[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dartmouth-Hitchcock Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":664},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,66,0,25,[9,50,77,98,123,154,177,204,231,262,284,315,339,369,391,413,437,458,488,513,538,567,587,612,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100610105","gastrointestinal-response-of-pediatric-cystic-fibrosis-patients-on-mediterranean-diet-100610105",false,"NCT07223255","Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean Diet","MedDietCF","Inclusion Criteria:\n\n* Male and female pediatric patient with cystic fibrosis age 3 and older\n* Nutritional status defined as a BMI Z-score of at least -1 or above\n* Confirm diagnosis of CF defined by 2 CF causing mutations on genetic testing or sweat chloride greater than 60 mEq\u002FL\n* Children with pancreatic insufficient CF and on PERT\n* Children with pancreatic sufficient CF not on PERT\n* Child must be on a full, solids based diet\n* Family willing to child adhere to an exclusive Mediterranean style diet for a period of 6 months\n* Child must be able to follow-up at regular CF clinic visits and attend any additional study visits if necessary\n\nExclusion Criteria:\n\n* Children with malnutrition\n* Children who require nutritional supplementation via any type of feeding tube\n* Children with poorly controlled CF lung disease\n* Children with advanced CF liver disease\n* Children with a comorbid gastrointestinal disease such as celiac disease, Crohn's disease or other malabsorptive process to be reviewed by PI\n* Children with significant food allergies or other gastrointestinal allergy\n* Family is unwilling to adhere to prescribed dietary intervention","ALL","3 Years","18 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","There is no study to date that has evaluated the impact or effect of a Mediterranean diet in children with CF. The goal of this study would be to help provide better guidance around questions the investigators, as CF care providers continue to receive from patients and families about how to best promote overall health in pediatric cystic fibrosis from a dietary perspective. Currently, the updated nutritional recommendations are variable and broad. Parents continue to search for more concrete guidance about how best to promote long-term health given the ever-increasing life expectancy of cystic fibrosis patients in this new area of advanced therapeutics. Given the changing landscape of the CF care in general, children are less likely to struggle with early life malnutrition, and it is becoming increasingly clear that high fat, high calorie diets are not beneficial nor are necessary for all children with CF.",[28,29],"Cystic Fibrosis (CF)","Cystic Fibrosis Gastrointestinal Disease",[31,32,33,34,35,36],"cfmed","meddiet","meddiet cf","mediterannean diet","cystic fibrosis","CF with Mediterranean diet","RECRUITING","2026-07-01",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":22},"2026-09-01",{"date":45,"type":22},"2027-06",{"name":47,"class":48},"Dartmouth-Hitchcock Medical Center","OTHER",2,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100556243","testing-a-mammography-decision-intervention-in-a-rural-setting-100556243","NCT06522568","Testing a Mammography Decision Intervention in a Rural Setting","Toward Optimization of a Mammography Decision Aid and Clinician Communication Intervention Trial for Rural Settings","Patient Inclusion Criteria:\n\n* Females\n* Aged 39-49\n* Upcoming appointment with a participating primary care provider (within 4 weeks)\n* English or Spanish-speaking\n\nPatient Exclusion Criteria:\n\n* Personal history of breast cancer (including lobular carcinoma in situ and ductal carcinoma in situ or atypical hyperplasia)\n* Mammogram in the prior 12 months\n\nClinician inclusion: Any practicing primary care provider at a participating site.","FEMALE","39 Years","49 Years",{"count":61,"type":22},39,[25],"The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention. This will be accomplished through two aims: (1) Refine, with community partner input, a clinical trial protocol to optimize engagement among patients and primary care providers (PCPs) practicing in rural settings. In consultation with patients, PCPs, and informatics experts, the study team will refine site selection, randomization, patient and PCP recruitment, and data collection protocols to meet the needs of the rural health care delivery system and participants. The result of this aim will be a modified protocol and intervention strategy that is acceptable to partners. (2) Adapt and test trial and intervention implementation features to achieve protocol acceptance and adherence. The investigators will pilot the adapted three-arm randomized trial protocol in rural primary care settings that compares the MyMammogram DA with or without a risk summary provided to the PCP pre-visit, relative to usual care. Implementing the trial in two phases (n=15 each) will systematically identify barriers and facilitators to trial participation to refine protocols. Participants will receive acceptability surveys and investigators will conduct qualitative interviews with patients and PCPs to understand experiences with trial implementation from multiple perspectives.",[65],"Breast Cancer",[67],"Screening","2026-06-20",{"date":70,"type":41},"2026-06-24",{"date":72,"type":41},"2025-09-01",{"date":74,"type":22},"2026-09-15",{"name":47,"class":48},3,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100535989","a-randomized-two-arm-proof-of-concept-study-testing-a-novel-approach-to-exercise-promotion-based-on-affect-regulation-100535989","NCT06258993","A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation","Increasing Physical Activity Among Breast Cancer Survivors: Use of the ORBIT Model to Refine and Test a Novel Approach to Exercise Promotion Based on Affect-regulation (Study 2)","Inclusion Criteria:\n\n* ≥18 years old\n* Within 5 years of completing primary cancer treatment (surgery, chemotherapy, and radiation) for Stage 0-III breast cancer\n* \\\u003C60 mins\u002Fweek moderate-vigorous physical activity (MVPA) with no major changes for the past 6- months\n* Own an Android or iPhone smartphone (or tablet) and willing to use it to complete app-based surveys during assessment periods\n* Willing to wear the ActiGraph monitor during assessment periods\n* Access to internet to complete REDCap survey assessments\n\nExclusion Criteria:\n\n* Non-English speaking\u002Fnot able to read English\n* Evidence of major contraindications for exercise (informed by the 2020 Physical Activity Readiness-Questionnaire (PAR-Q)+)\n* Currently pregnant\n* History of severe mental illness or currently taking mood stabilizing medications (antipsychotics, anticonvulsants, or lithium)\n* Evidence of moderate-severe depressive symptoms (indicated by a score≥ 10 on the Patient Health Questionnaire-8)\n* Evidence of moderate-severe cognitive impairment (indicated by a score \\\u003C 3 on a 6-item cognitive screener)\n* Evidence of clinically significant substance use as indicated by a score of ≥ 2 on the CAGE- AID screener.",{"count":85,"type":22},85,[25],"The goal of this clinical trial is to test the effect of an affect-based exercise prescription on moderate-vigorous physical activity participation among survivors of breast cancer who completed primary treatment within the last 5 years. The main questions it aims to answer are:\n\n1. Do at least 50% of participants assigned to the affect-based exercise prescription engage in ≥90 minutes of moderate-vigorous physical activity by the end of 12-weeks follow-up?\n2. What level of satisfaction do breast cancer survivors who receive the affect-based exercise prescription report relative to breast cancer survivors who receive an effort-based exercise prescription.\n3. What proportion of participants assigned to the affect-based exercise prescription stay enrolled in the study relative to the number of participants who stay enrolled in the effort-based exercise prescription.\n\nAll participants will:\n\n* Be assigned to either the Affect-based exercise prescription or the Effort-based exercise prescription.\n* Participate in two meetings with a member of the study team meant to help them get started increasing weekly exercise. These meetings are the same for all participants.\n* Be asked to wear an activity monitor and respond to brief surveys for 10 straight days at 4 points in time: Baseline, 2weeks, 6weeks, and 12weeks.",[65],"2026-06-19",{"date":91,"type":41},"2026-06-23",{"date":93,"type":41},"2024-04-16",{"date":95,"type":22},"2026-08-30",{"name":47,"class":48},1,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":97},"100499240","individualized-dose-escalation-of-5-fu-for-gastrointestinal-cancer-100499240","NCT05780684","Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer","Adaptive, Individualized Dose Escalation of Fluorouracil-Based Chemotherapy for Gastrointestinal Cancer: Pilot Study of the FOX Regimen","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of metastatic or locally advanced\u002Finoperable colorectal cancer or non-colorectal gastrointestinal cancer (including cancers of the stomach, esophagus, appendix, small bowel, and ampulla)\n* Clinically appropriate staging imaging of the chest, abdomen, and pelvis performed within 30 days prior to registration\n* ECOG Performance Status: 0-1\n\nExclusion Criteria:\n\n* Any prior receipt of oxaliplatin or fluoropyrimidine chemotherapy (other than radiation-sensitizing fluoropyrimidine chemotherapy)\n* Prior receipt of systemic chemotherapy in the 6 months prior to Day 1 of Cycle 1 of FOX (other than radiation-sensitizing chemotherapy)\n* Known mismatch repair deficiency or microsatellite instability-high disease\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency, as identified by clinically indicated screening\n* Any confirmed second malignancy that is likely to require systemic therapy during the course of the six-month study period, in the opinion of the enrolling investigator\n* Any of the following baseline laboratory abnormalities:\n\n  * Absolute neutrophil count (ANC) \\\u003C 2,500\u002Fmm3\n  * Platelet count \\\u003C 100,000\u002Fmm3\n  * Hemoglobin \\\u003C 9 g\u002FdL\n  * Creatinine \\> 1.5 x ULN\n  * Total bilirubin \\> 1.5 x ULN\n  * AST\u002FALT \\> 5 x ULN\n  * Patients who are unable to provide informed consent\n  * Patients who are pregnant or breastfeeding\n  * Patients who are incarcerated, homeless, or have active substance use disorders",{"count":106,"type":22},36,[25],"This is a single-arm clinical trial to evaluate the feasibility of a chemotherapy regimen using adaptive, individualized dose escalation of 5-FU chemotherapy for patients who have good tolerance of the initial dose. Study participants will also receive oxaliplatin chemotherapy together with 5-FU, at standard doses. The goal of the study is to examine the feasibility and effectiveness of this approach, using individualized dose escalation of 5-FU in patients who do not have serious side effects at lower doses.",[110,111,112,113,114],"Colorectal Cancer","Esophagus Cancer","Appendix Cancer","Small Bowel Cancer","Ampullary Cancer","2026-06-18",{"date":117,"type":41},"2026-06-22",{"date":119,"type":41},"2023-07-14",{"date":121,"type":22},"2027-12",{"name":47,"class":48},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100641653","ipath-for-cp-pilot-100641653","NCT07631247","iPath for CP Pilot","Improving Screening and Access to Treatment for Depression in Care Partners of People Living With Dementia","care partners","Inclusion Criteria:\n\n* For 2 Week iPath\\*CP Pilot:\n\n  1. Adults (≥18 years)\n  2. Care partners of persons with dementia who score ≥5 on the PHQ-8 AND PHQ-9 screen\n  3. Can communicate in English\n  4. Have access to an Android based or Apple iOS based phone or tablet capable of running the iPath application.\n\nFor Debrief Interviews:\n\n* Care partners: Interviews will be conducted with a purposeful sample of 6 patients already consented into the study at the completion of T1 data collection, ensuring representation by sex (male\u002Ffemale), perceived usability (low\u002Fhigh) of iPath\\*CP and race\u002Fethnicity.\n* Clinicians: Interviews will be conducted with clinicians and clinical staff who had patients involved in the project.\n\nExclusion Criteria:\n\n* Care partners with:\n\n  1. PHQ-8 score \\\u003C5\n  2. Answering positively for question 9 of the PHQ-9 who also screen positive for suicidal ideation with method, intent, plan or a recent prior suicide\u002Fself-harm attempt, as determined by a positive endorsement of items 3, 4, 5 or 6b (\"Past 3 Months\") on the Columbia-Suicide Severity Rating Scale (C-SSRS) and determined by Dr. Mistler, Psychiatrist at DH, not to be eligible.\n  3. With bipolar disorder or psychosis (documented in the electronic medical record \\[EMR\\])\n  4. With significant cognitive impairment (documented in the EMR or self-reported during eligibility screening)\n  5. With no access to an Android or Apple device\n\nFor Debrief Interviews:\n\n* Patients: Participants withdrawn from the 2 Week iPath\\*CP Pilot.\n* Clinicians: None.",{"count":132,"type":22},15,[25],"Depression is a significant problem in care partners of people living with dementia; despite the expansion of options for accessing evidence-based treatments, most care partners of people living with dementia are not screened for depression and do not receive treatment. The objective of this project is to identify a screening method for depression that is feasible and acceptable to care partners and to adapt an innovative pathway to online evidence-based treatment for depression (iPath\\*D) as a means of increasing mental health literacy, screening rates and treatment access for care partners of people living with dementia. The results are expected to have a major positive impact by providing proof-of-principle for the use of an online pathway to evidence based treatment with the potential for reaching an unprecedented number of care partners who have unmet mental health needs.",[136],"Depression - Major Depressive Disorder",[138,139,140,141,142,143,144],"depression","caregiver","AD\u002FADRD","Alzheimer's disease","dementia","care partner","app","NOT_YET_RECRUITING","2026-06-12",{"date":148,"type":41},"2026-06-16",{"date":150,"type":22},"2026-06",{"date":152,"type":22},"2027-02",{"name":47,"class":48},{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":161,"sex":17,"minAge":19,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100625159","feasibility-of-modulating-cognitive-control-in-ocd-100625159","NCT07419009","Feasibility of Modulating Cognitive Control in OCD","Evaluating Frontal Pole as a Window to Modulation of Cognitive Control in OCD","Inclusion Criteria:\n\n* Current primary DSM-5 OCD diagnosis and current Y-BOCS total score of ≥16 (OCD group, only) or no current diagnosis of an emotional disorder, and no known history of OCD, PTSD, anxiety disorder(s), or recurrent major depressive disorder (Healthy participant group, only)\n* 18-60 years of age\n* ability to speak, read, write, and understand English sufficiently well to complete study procedures and provide informed consent\n* psychotherapy and\u002For psychiatric medication use remain stable for 6 weeks prior to study entry\n\nExclusion Criteria:\n\n* Presence of current psychiatric diagnosis (healthy control group, only)\n* active substance use disorder\n* history of mania or hypomania, or lifetime presence of significant psychotic symptoms\n* active suicidal or homicidal ideation\n* use of medications known to reduce seizure threshold (e.g., stimulants)\n* organic brain disease or injury representing a contraindication to TMS\n* any health problems that would interfere with safe and\u002For practical study participation, including contraindications to TMS (e.g., seizure disorder, presence of metal hardware that would come in close contact with the discharging coil)\n* current pregnancy or planning to become pregnant during the study period",true,"60 Years",{"count":164,"type":22},12,[25],"This study tests out procedures to look at whether a type of brain stimulation called transcranial magnetic stimulation impacts flexible shifts in behavior in obsessive-compulsive disorder (OCD). This study examines whether study procedures are feasible and acceptable to people participating in the study, but does not determine whether this type of brain stimulation causes changes.",[168],"Obsessive-Compulsive Disorder (OCD)","2026-05-22",{"date":171,"type":41},"2026-05-27",{"date":173,"type":22},"2026-06-15",{"date":175,"type":22},"2026-10-30",{"name":47,"class":48},{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":185,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":97},"100639217","phase-1-apbi-re-irradiation-100639217","NCT07612254","aPBI Re-irradiation","REPEAT: RE-irradiation With a Partial brEast, Accelerated Technique: A Single-Center, Multi-site, Prospective, Phase I\u002FII Clinical Trial","REPEAT","Inclusion Criteria\n\n1. Patients who have histologically-confirmed, second, ipsilateral breast cancer which was diagnosed more than one year after completing breast conserving therapy.\n2. Patients must have received prior radiotherapy to the breast\n3. Patients must have an intact, involved breast.\n4. Patients must meet ASTRO 2023 guidelines for a strong recommendation for partial breast irradiation.\n\n   * Grade 1-2 disease\n   * ER-positive histology\n   * Tumor size up to 2 cm\n   * Patient's age 40 or older\n5. Patients who will undergo breast radiation therapy at D-H Lebanon, D-H St. Johnsbury, or Cheshire Medical Center.\n6. Patients must have a lumpectomy cavity that can be delineated on CT scan.\n7. Patients who are able to provide informed consent.\n8. Females of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entry.\n9. Females of childbearing potential must not be pregnant and not lactating and willing to use medically acceptable form of contraception during radiation therapy.\n\nExclusion Criteria\n\nPatients who meet any of the criteria below may NOT participate in this study:\n\n1. Patients who have not received prior radiotherapy to the ipsilateral breast.\n2. Patients who do not meet ASTRO 2023 guidelines for a strong recommendation for partial breast irradiation, including those who meet criteria for conditionally recommended, conditionally not recommended, and not recommended for partial breast irradiation.\n3. Patients who are \\\u003C 40 years of age.\n4. Patients with breast implants or other breast reconstruction.\n5. Patients who received a prior course of aPBI or breast brachytherapy in the ipsilateral breast.\n6. Patients who are actively receiving treatment or within 1 year of treatment from another malignancy, excluding non-melanoma skin cancers.\n7. Patients who are pregnant.\n8. Patients who are unable to provide informed consent.\n9. Patients who decline participation in the study.\n10. Patients with active systemic lupus erythematosus, or any history of scleroderma, dermatomyositis with active rash are excluded.","40 Years",{"count":187,"type":22},30,[189,190],"PHASE1","PHASE2","This study is to determine whether acute treatment-associated adverse events following breast re-irradiation with aPBI are acceptably low and to assess local control following breast re-irradiation with aPBI. An exploratory aim is to assess cosmetic outcomes following breast re-irradiation with aPBI.",[193],"Breast Cancer Recurrent",[195],"Ipsilateral","2026-05-20",{"date":198,"type":41},"2026-05-28",{"date":200,"type":22},"2026-06-03",{"date":202,"type":22},"2033-04",{"name":47,"class":48},{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":220,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":230,"locationsCount":49},"100548748","self-administered-one-of-a-kind-approach-to-epilepsy-therapy-through-a-web-based-music-application-100548748","NCT06425029","Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application","SONATA: Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application","SONATA","Inclusion Criteria:\n\n* Adults with medication-refractory focal epilepsy who have undergone RNS implantation at least six months prior and are in the judgement of the treating physician on a stable RNS regimen in terms of stimulation\n* Willing to attend all study visits and complete all required study procedures\n* Access to private or public wireless data service at regular intervals\n* Access to personal mobile device\n\nExclusion Criteria:\n\n* Documentation of a musicogenic, or auditory-triggered focal seizure semiology\n* Participant is unable to reasonably participate in study tasks as determined by the investigator\n* Inability to obtain informed consent from the patient or legally authorized representative",{"count":213,"type":22},24,[25],"This is a prospective, placebo-controlled, double-blinded randomized study of self-administered auditory intervention in a naturalistic home environment.",[217,218,219],"Epilepsy","Refractory Epilepsy","Music",[221,222,223,224],"music","epilepsy","responsive neurostimulation","interictal discharge","2026-05-18",{"date":196,"type":41},{"date":228,"type":41},"2025-07-22",{"date":121,"type":22},{"name":47,"class":48},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":246,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":76},"100512660","comparing-healthcare-visit-recording-and-open-notes-to-improve-chronic-illness-care-experience-in-older-adults-100512660","NCT05955339","Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults","Comparing Healthcare Visit Recording and Open Notes to Improve the Chronic Illness Care Experience for Older Adults (The CHRONICLE Trial)","CHRONICLE","PATIENTS:\n\nInclusion Criteria:\n\n* ≥ 65 years;\n* With multimorbidity (diabetes or hypertension plus one of the following: arthritis (osteoarthritis and rheumatoid arthritis), asthma, atrial fibrillation, Alzheimer's disease and related dementia (not severe), cancer, chronic obstructive pulmonary disease, depression, heart disease, heart failure, hyperlipidemia, osteoporosis, kidney disease and stroke. Patients with diabetes plus hypertension are eligible.\n* Have had two or more clinic visits in the previous 12 months;\n* Plan on receiving ongoing care at the clinic with the enrolled clinician for the subsequent 6 months;\n* Do not have vision or hearing problems that cannot be corrected; and\n* Have not recorded a clinic visit for personal use in the past 6 months\n\nExclusion Criteria:\n\n* With no capacity to consent to the project;\n* With schizophrenia and other psychotic disorders, current substance-use disorders, uncorrected hearing or visual impairment with no adjustments to support accessing the interventions or surveys;\n* Living in skilled nursing homes or hospice, because they engage less in self-management;\n* With cognitive impairment as identified by a score of ≤4 on the six-item screener (SIS)\n* Lacking internet access;\n* Who do not speak English or Spanish;\n* Who (i) do not have access to a personal email, (ii) do not have an email address shared with a family member or patient-identified caregiver, and\u002For (iii) are not interested in creating a personal email as this would prevent them from engaging with the intervention(s); and\n* Who do not wish to create a patient portal account, if they do not already have one as this would prevent them from engaging with the intervention(s).\n\nCAREGIVERS:\n\nInclusion criteria:\n\n* Agree to their identified role as a caregiver;\n* Speak English or Spanish;\n* Have capacity to consent to research participation; and\n* ≥ 18 years.\n\nExclusion criteria:\n\n* No capacity to consent to the project;\n* Living in skilled nursing homes or hospice;\n* Lacking internet access; or\n* Do not speak English or Spanish",{"count":240,"type":22},1022,[25],"CHRONICLE is a randomized trial assessing the comparative effectiveness of providing written visit information via the patient portal (NOTES) versus NOTES plus visit audio recording (AUDIO) to older adult patients with chronic diseases on quality of life and other outcomes. During the trial, the team will also invite caregivers identified by patients to join the project.",[244,245],"Diabetes Mellitus","Hypertension",[247,244,245,248,249,250,251,252,253,254],"Audio Recording","Patient-centered communication","Self-management","Older adults","Chronic conditions","After visit summary","Quality of life","Multimorbidity","2026-05-15",{"date":225,"type":41},{"date":258,"type":41},"2024-01-24",{"date":260,"type":22},"2027-06-14",{"name":47,"class":48},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":97},"100637813","phase-4-flush-lyse-operate-100637813","NCT07592520","Flush, Lyse, Operate","Flush, Lyse, Operate: A Pilot Trial of Step-Wise Escalation for Pleural Infection: FLO Trial","FLO","Inclusion Criteria:\n\n* Age 18+\n* Complicated Parapneumonic Effusion or Empyema Requiring Thoracostomy\n* Are able to personally or have a designated medical decision maker provide consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Have received any intrapleural medications prior to enrolment via current chest tube\n* Have a contraindication to tPA\u002FDNase:\n\n  * Anticoagulation\n  * Active hemorrhage\n  * Allergy to tPA\u002FDNase\n  * Pregnancy\n* Are unable to personally or do not have a designated medical decision maker provide consent",{"count":187,"type":22},[272],"PHASE4","The goal of this observational study is to learn if saline results in improvement for patients with infection of their plerual space. The main question it aims to answer is:\n\nWhat is the time to chest tube removal? Do these patients after need to escalate to fibrinolytics? Do these patients after need to escalate to surgery?\n\nParticipants will:\n\n* Receive receive saline into their pleural space through an existing chest tube\n* If they fail to improve, which will be determined by fluid size after treatment or signs of persistent infection, they will receive fibrynolytics through an existing chest tube\n* If they fail to improve, which will be determined by fluid size after treatment or signs of persistent infection, they will be referred to surgery.",[275,276],"Complicated Parapneumonic Effusion","Empyema, Pleural","2026-05-11",{"date":225,"type":41},{"date":280,"type":22},"2026-04",{"date":282,"type":22},"2027-04",{"name":47,"class":48},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":17,"minAge":291,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":294,"conditions":295,"keywords":301,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":97},"100625272","tf-cbt-for-autistic-youth-pilot-implementation---open-pilot-100625272","NCT07420478","TF-CBT for Autistic Youth Pilot Implementation - Open Pilot","Implementation Science-Guided Pilot Study of Trauma-Focused Cognitive Behavioral Therapy for Autistic Youth in Community Mental Health Settings","Inclusion Criteria for Therapists\n\n1. Employed as a clinician at a participating Community Mental Health Center (CMHC; publicly-funded mental health program) for at least 6 months.\n2. Trained in TF-CBT.\n3. Has an eligible autistic youth on current caseload (see below).\n\nInclusion Criteria for Child Participants\n\n1. Between 6 and 18 years old (up to 17 years, 11 months).\n2. Current medical diagnosis of autism.\n3. Has a non-offending caregiver who is able to participate in treatment (i.e., caregiver who is not the perpetrator of the abuse\u002Fother trauma).\n4. Initiated outpatient psychotherapy services from participating therapist within enrolled CMHC.\n5. A moderate level of trauma-related distress as measured by the Child and Adolescent Trauma Screen-2 (CATS-2).\n\nExclusion Criteria for Child Participants\n\n1\\. Does not present with trauma-related distress (score falls within the \"Normal\" range as measured by the Child and Adolescent Trauma Screen-2 Self- and Parent-Report).","6 Years",{"count":213,"type":22},[25],"Compared to the general population, autistic youth are at increased risk for both exposure to potentially traumatic events and trauma-related symptoms following trauma exposure. Autistic people identify approaches to effectively addressing trauma as a top mental health research priority, yet providers in community settings often report inadequate training in trauma treatment. The purpose of this study is to conduct an open pilot to evaluate the feasibility and acceptability of an evidence-based intervention for youth affected by trauma, Trauma-Focused Cognitive Behavioral Therapy (TF-CBT), that has been modified for autistic youth served in Community Mental Health Centers.",[296,297,298,299,300],"Autism Spectrum Disorder","PTSD and Trauma-related Symptoms","Autism","Trauma and Stressor Related Disorders","Mental Health Services",[298,302,303,304,305,306,307],"Trauma","PTSD","Mental health symptoms","TF-CBT","Implementation science","Trauma-Focused Cognitive Behavioral Therapy",{"date":309,"type":41},"2026-05-13",{"date":311,"type":41},"2026-05-05",{"date":313,"type":22},"2027-02-28",{"name":47,"class":48},{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100614401","phase-1-aby-029-head--neck-trial-100614401","NCT07279116","ABY-029 Head & Neck Trial","Phase 1 Trial of ABY-029 Fluorescence in Patients With Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Preoperative diagnosis of head and neck squamous cell carcinoma with planned surgical resection of the oral cavity, oropharynx, larynx, or hypopharynx.\n2. Tumor judged to be operable.\n3. Valid informed consent by participant.\n4. Age ≥ 18 years old.\n5. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with a medical history of (Grade 2 or higher) hepatic\u002Frenal function compromise.\n2. Prisoners\n3. Individuals who are pregnant or breast feeding.\n4. Patients on experimental or approved anti-EGFR targeted therapies.",{"count":213,"type":22},[189],"The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach head and neck squamous cell carcinomas (HNSCC) so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.",[326],"Head and Neck Squamous Cell Carcinoma",[328,329,330,331],"ABY-029","Affibody","Molecular Fluorescence-Guided Surgery","Epidermal Growth Factor Receptor (EGFR)",{"date":333,"type":41},"2026-05-07",{"date":335,"type":22},"2026-06-30",{"date":337,"type":22},"2028-06-30",{"name":47,"class":48},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":17,"minAge":347,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":358,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":368},"100486305","colonoscopy-vs-stool-testing-for-older-adults-with-colon-polyps-100486305","NCT05612347","Colonoscopy vs Stool Testing for Older Adults With Colon Polyps","Colonoscopy Versus Stool-based Testing for Older Adults With a History of Colon Polyps","COOP","Inclusion Criteria:\n\n* English or Spanish speaking\n* Personal history of colorectal polyps\n* Most recent colonoscopy with ≤2 non-advanced polyps\n* Currently due or coming due within 12 months for colonoscopy\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Personal history of colorectal cancer\n* Personal history of genetic syndrome with high risk for colorectal cancer (e.g. Lynch Syndrome, Familial Adenomatous Polyposis Syndrome (FAP), or Serrated Polyposis Syndrome)\n* Personal history of inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease)\n* Most recent colonoscopy with advanced polyp(s) or ≥3 non-advanced polyps\n* Patients unlikely to benefit from polyp surveillance (e.g., history of heart disease or coronary artery disease with treatment in the last 6 months, heart failure affecting function, lung disease requiring use of home oxygen, stroke within the last 4 months, dementia affecting activities of daily living (ADL) or instrumental activities of daily living (IADL), severe liver disease requiring the use of certain medications to control fluid, confusion, or bleeding, severe kidney disease requiring dialysis, or a new cancer diagnosis within the last year)\n* Patients unable to provide written informed consent","65 Years","82 Years",{"count":350,"type":22},8946,[25],"This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.",[354,355,356,110,357],"Colorectal Polyp","Colorectal Neoplasms","Colorectal Adenoma","Digestive System Disease",[359,360],"Colonoscopy","Fecal immunochemical test (FIT)","2026-05-01",{"date":333,"type":41},{"date":364,"type":41},"2023-06-14",{"date":366,"type":22},"2035-12-31",{"name":47,"class":48},22,{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":23,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":97},"100414613","phase-2-low-dose-naltrexone-for-the-treatment-of-painful-diabetic-neuropathy-100414613","NCT04678895","Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy","Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy, a Small, Randomized, Double-blind, Placebo-controlled Crossover Trial","Inclusion Criteria:\n\n1. Diagnosis of Painful Diabetic Neuropathy (PDN) for \\>6 months\n2. Has failed at least one prior standard treatment for PDN (Gabapentin, duloxetine, etc)\n3. No other known causes of lower extremity neuropathic pain\n4. Subjects capable of giving informed consent\n5. Greater than 18 years of age\n6. Stable on all current non-opioid pain medication for at least 1 month\n7. English as primary language\n\nExclusion Criteria:\n\n1. Known allergy to naltrexone or naloxone\n2. Presence of known causes of lower extremity neuropathic pain not attributed to PDN\n3. Active substance use disorder or alcohol use disorder as defined by DSM-V (The Diagnostic and Statistical Manual of Mental Disorders)\n4. Current treatment for substance use disorder or alcohol use disorder\n5. Current opioid therapy or on opioid therapy within the past 1 month",{"count":377,"type":22},35,[190],"Diabetes affects more than 30 million people in the United States and is a leading cause of morbidity. Over 25% diabetics also suffer from debilitating painful diabetic neuropathy in the lower legs and feet. This pain can be severe, difficult to control, and have a significant negative impact on quality of life. Opioid medications have historically been a mainstay of treatment for this pain, despite the risks. As the death toll from the U.S. opioid epidemic continues to rise, the need for quality alternative non-opioid medications to treat pain becomes more urgent. One of these potential medications is Low-Dose Naltrexone (LDN). This drug is reported to work by enhancing the body's natural pain relieving mechanisms and decreases inflammation by targeting specific cells called microglia which have been shown to influence chronic pain. LDN has been shown to be a safe medication with minimal side effects. Its efficacy has been demonstrated in other painful conditions but has never been fully studied for treating painful diabetic neuropathy. The goal of this randomized, placebo-controlled trial is to determine if LDN is effective for treating the pain caused by diabetic neuropathy. LDN's mechanism of action is well suited to treating painful diabetic neuropathy, and LDN shows significant promise as a safe, non-opioid alternative that can decrease pain and improve quality of life for those suffering from this painful condition.",[381],"Painful Diabetic Neuropathy",[383,381],"Low-Dose Naltrexone",{"date":385,"type":41},"2026-05-06",{"date":387,"type":41},"2020-12-22",{"date":389,"type":22},"2026-12",{"name":47,"class":48},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":397,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":23,"phases":400,"briefSummary":401,"conditions":402,"keywords":404,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":411,"leadSponsor":412,"locationsCount":97},"100627627","epileptiform-potential-of-fully-immersive-virtual-reality-100627627","NCT07451093","Epileptiform Potential of Fully Immersive Virtual Reality","Inclusion Criteria:\n\n* subjects with known or suspected diagnosis of epilepsy with interictal epileptiform discharges seen during current or prior EEG recording\n* Age greater than or equal to 13 years\n\nExclusion Criteria:\n\n* Age less than 13 years (infants, children)\n* Pregnancy\n* Incarceration\n* Moderate-severe cognitive impairment","13 Years",{"count":399,"type":22},40,[25],"The goal of this interventional study is to determine if the use of virtual reality headsets results in an increased risk of seizure in adolescent and adult individuals with epilepsy. The main question it aims to answer are:\n\n\\- does use of virtual reality headsets with hand controllers result in a higher risk of seizure compared to use of virtual reality headsets without hand controllers Participants will be asked to wear a virtual reality headset during continuous video EEG recording and EEG with be evaluated during three phases: with display turned off, with display turned on without hand controllers, and with display turned on with hand controllers.",[217,403],"Seizure",[217,403,405,406,407],"Virtual Reality","VR","Reflex epilepsy","2026-04-30",{"date":385,"type":41},{"date":150,"type":22},{"date":45,"type":22},{"name":47,"class":48},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":57,"minAge":19,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":97},"100494310","phase-2-study0200174022sch740-estradiol-for-er-advanced-breast-cancer-esther-100494310","NCT05716516","STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)","Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer","ESTHER","Inclusion Criteria:\n\n* Post-menopausal women with ER+ breast cancer.\n* Metastatic or locoregional recurrence not amenable to treatment with curative\n* intent.\n* Received ≥1 prior line of endocrine-based therapy (e.g., including tamoxifen, aromatase inhibitors, fulvestrant, or combinations) in the advanced\u002Fmetastatic setting\n\nExclusion Criteria:\n\n* During the study Treatment Phase with 17b-estradiol, no concurrent anti-cancer therapies are allowed with the following exceptions:\n\n  * Exception: Trastuzumab is allowed for the treatment of subjects with a history of HER2+ disease, and will be used at the physician's discretion.\n  * Exception: Anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) are permitted.\n* Any investigational cancer therapy in the last 3 weeks.\n* Known CNS disease, unless clinically stable for ≥ 3 months.\n* History of any of the following:\n\n  * Deep venous thrombosis.\n  * Pulmonary embolism.\n  * Stroke.\n  * Acute myocardial infarction.\n  * Congestive heart failure.\n  * Previous malignancy not treated with curative intent, or with an estimated recurrence risk ≥30%.",{"count":106,"type":22},[190],"Determine whether subjects harboring ESR1-mutant\u002Famplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer",[425],"Metastatic Breast Cancer",[427,428,429,430],"Metastatic","Locally advanced","Estradiol therapy","Estrogen therapy",{"date":311,"type":41},{"date":433,"type":41},"2023-05-04",{"date":435,"type":22},"2027-05",{"name":47,"class":48},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":450,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":457,"locationsCount":97},"100625899","piloting-an-insomnia-treatment-in-patients-with-ulcerative-colitis-100625899","NCT07428629","Piloting an Insomnia Treatment in Patients With Ulcerative Colitis","RISE-UC","Inclusion Criteria:\n\n* Active UC based on PRUCSI\n* Insomnia Severity Index score \\> 8 and SOL or WASO \\> 30 minutes\n* Stability of sleep \\& UC meds for \\> 3 months\n* Access to internet or cell phone service sufficient for telehealth\n\nExclusion Criteria:\n\n* PHQ-9 depression score \\> 15\n* GAD-7 anxiety score \\> 15\n* Unstable major psychiatric condition (e.g., bipolar disorder, psychotic disorder)\n* Current alcohol or substance abuse\n* Current opioid use for pain control\n* Current systemic corticosteroid use\n* Current pregnancy or nursing\n* Ileostomy or colostomy\n* Diagnosis of seizure disorder\n* Diagnosis of sleep apnea\n* Diagnosis of restless leg syndrome or positive Cambridge-Hopkins RSLq screen\n* Night shift, rotating shift work, or frequent travel outside of time zone\n* Residence in a state where we cannot conduct telehealth visits",{"count":21,"type":22},[25],"The goal of this clinical trial is to learn if telehealth-based Cognitive Behavioral Therapy for Insomnia (CBT-I) adapted for Ulcerative Colitis (UC) works to treat insomnia in adults with UC. The main questions it aims to answer are:\n\n* Is telehealth-based CBT-I adapted for UC feasible and acceptable to participants?\n* Does CBT-I for UC impact insomnia severity and sleep continuity?\n\nParticipants will:\n\n* Answer questionnaires online before and after treatment\n* Complete an online daily sleep diary before, during, and after treatment\n* Participate in 5 telehealth treatment visits over 7-8 weeks\n* Participate in 5-10-minute phone calls between treatment visits",[448,449],"Insomnia","Ulcerative Colitis",[451],"telehealth","2026-04-29",{"date":311,"type":41},{"date":455,"type":41},"2026-04-17",{"date":43,"type":22},{"name":47,"class":48},{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":464,"enrollmentInfo":465,"targetDuration":4,"studyType":23,"phases":467,"briefSummary":468,"conditions":469,"keywords":472,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":487},"100585148","enhancing-engagement-by-integrating-goals-and-concerns-that-matter-to-patients-100585148","NCT06898593","Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients","Inclusion Criteria:\n\n* Patients enrolled in the Collaborative Care Model (CoCM) at Dartmouth Health\n\nExclusion Criteria:\n\n* Patients not enrolled in the Collaborative Care Model (CoCM) at Dartmouth Health","100 Years",{"count":466,"type":22},2448,[25],"The goal of this clinical trial is to learn if adding patients' goals and concerns to measurement-based collaborative care can tailor care and provide a more holistic view of treatment, thereby improving engagement in care among adult patients receiving collaborative care. The main questions it aims to answer are:\n\n* Does using a clinical decision support system (which includes an enhanced pre-visit questionnaire and patient-level dashboard) improve patient engagement in the collaborative care model?\n* Does using a clinical decision support system improve patient and clinician satisfaction with care?\n\nResearchers will compare the enhanced collaborative care with traditional collaborative care.\n\nPatient participants will complete pre-visit questionnaires before their collaborative care appointments. Responses will be viewed by the clinician and\u002For patient in a visual dashboard inside the electronic health record.",[470,471],"Anxiety Disorders","Depression Disorders",[473,474,475,476,477,478,479],"Collaborative Care Model","pre-visit questionnaire","dashboard","clinical decision support system","Depression","Anxiety","integrated behavioral health and primary care","2026-04-27",{"date":452,"type":41},{"date":483,"type":41},"2025-04-02",{"date":485,"type":22},"2028-07-31",{"name":47,"class":48},6,{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":496,"phases":4,"briefSummary":497,"conditions":498,"keywords":502,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":510,"leadSponsor":512,"locationsCount":97},"100634971","in-vivo-imaging-of-the-olfactory-epithelium-using-confocal-laser-endomicroscopy-100634971","NCT07546617","In Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy","In Vivo Imaging of Olfactory Epithelium in Humans With Olfactory Impairment Using Confocal Laser Endomicroscopy","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Undergoing endoscopic sinus or endonasal skull base surgery while under - general anesthesia where the nasal turbinate is accessible\n* Able to complete study questionnaires and psychophysical smell testing\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to fluorescein\n* Pregnancy\n* Medical instability precluding participation\n* Severe anatomic obstruction preventing safe access to the olfactory cleft and nasal turbinate\n* Any other safety concern identified by the investigator",{"count":106,"type":22},"OBSERVATIONAL","This research is being done to better characterize the part of the nose that helps us smell. Currently, the only ways to study smell loss mostly rely on how people report it, rather than being able to see the underlying structures directly. In this study, we will use a special microscope (Confocal Laser Endomicroscopy (CLE)), originally developed for brain tissue, to look at the part of the nose that helps to detects smell. We hope to identify the tiny structures in that area and see how they might be different in people who have smell loss compared to those who do not.",[499,500,501],"Endonasal Surgery","Endoscopic Sinus Surgery","Olfactory Dysfunction",[503,500,504,505,501],"Confocal Laser Endomicroscopy","Smell Loss","Endonasal Skull Base Surgery","2026-04-16",{"date":508,"type":41},"2026-04-23",{"date":38,"type":22},{"date":511,"type":22},"2027-07-31",{"name":47,"class":48},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":520,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":523,"briefSummary":524,"conditions":525,"keywords":528,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":76},"100526410","phase-1-a-study-of-tetrathiomolybdate-tm-plus-capecitabine-100526410","NCT06134375","A Study of Tetrathiomolybdate (TM) Plus Capecitabine","Novel Targeting of the Microenvironment to Decrease Metastatic Recurrence of High-Risk TNBC: A Randomized Phase II Study of Tetrathiomolybdate (TM) Plus Capecitabine in Patients With Breast Cancer at High Risk of Recurrence","Inclusion Criteria:\n\n1. Patients must have histologically confirmed breast malignancy that is Triple negative tumors as defined as ER and PR \\\u003C1% and HER2 negative as per ASCO\u002FCAP guidelines\n2. The patient must have completed standard neoadjuvant chemotherapy which constitutes at least 6 cycles of chemotherapy.\n3. Phase Ib: Patients must have residual invasive carcinoma, at minimum in one of the following capacities: (1) node positive disease after treatment without residual invasive carcinoma in the breast; (2) RCB 2 or RCB 3 MDAH Calculator; Standard therapy consists of the following: (1) Local therapy: (a) Lumpectomy or mastectomy to negative margins. (b) Sentinel lymph node biopsy or axillary node dissection; (c) Radiation therapy to breast if patient received a lumpectomy and per investigator choice if considering chest wall\u002Fextended field RT. (2) Systemic therapy: Prior chemotherapy is required for patients entered on the trial. Neoadjuvant treatment should consist of the following standard therapy: Anthracycline and taxane-based therapy (i.e. AC-\\>T, AC-\\>Tcarbo, Keynote 522 regimen) or a non-anthracycline based chemo and immunotherapy regimen (NeoPACT). Patients must have received neoadjuvant Pembrolizumab for the phase Ib only and plan to continue it in the adjuvant setting for at least the first cycle of treatment.\n\n   Randomized Phase 2: Patients must have residual invasive carcinoma, at minimum in one of the following capacities: (1) node positive disease after treatment without residual invasive carcinoma in the breast; (2) RCB 2 or RCB 3 MDAH Calculator; Standard therapy consists of the following: (1) Local therapy: (a) Lumpectomy or mastectomy to negative margins. (b) Sentinel lymph node biopsy or axillary node dissection; (c) Radiation therapy to breast if patient received a lumpectomy and per investigator choice if considering chest wall\u002Fextended field RT. (2) Systemic therapy: Prior chemotherapy is required for patients entered on the trial. Neoadjuvant treatment should consist of the following standard therapy: Anthracycline and taxane-based therapy (i.e. AC-\\>T, AC-\\>Tcarbo, Keynote 522 regimen) or a non-anthracycline based chemo and immunotherapy regimen (NeoPACT). Pembrolizumab is allowed. Patients will be stratified by: (1) Treatment (chemotherapy vs chemotherapy + immunotherapy); (2) Age (Age ≤ 40 yrs vs \\> 40 yrs); and (3) RCB 2 vs RCB 3. These important stratification factors represent variables that are known to affect outcome for patients with TNBC.\n4. At least two weeks must have elapsed from last chemotherapy or radiation therapy. At least 4 weeks must have elapsed from most recent surgery.\n5. No clinical or radiologic evidence of disease after surgery and\u002For systemic treatment (by CT scan of chest, abdomen and pelvis and bone scan or PET scan prior to enrollment).\n6. Previous treatment with capecitabine is not allowed.\n7. Because no dosing or adverse event data are currently available on the use of TM in patients \\\u003C18 years of age, children are excluded from this study.\n8. KPS 90 or 100.\n9. Life expectancy of greater than 3 months.\n10. Patients must have normal organ and marrow function as defined below:\n\n    * hemoglobin \\>10mg\u002FdL\n    * absolute neutrophil count \\>1,500\u002F µL\n    * platelets \\>100,000\u002FµL\n    * total bilirubin \\\u003C1.5 x normal institutional limits\n    * AST (SGOT)\u002FALT (SGPT) \\\u003C1.5 X institutional upper limit of normal\n11. Antiresorptive therapy and denosumab may be administered.\n12. Patients must be on stable medical therapy for at least 2 weeks if they are being treated medically for their chemotherapy induced peripheral neuropathy.\n13. The effects of TM on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n14. Ability to understand and the willingness to sign a written informed consent document.\n15. Normal B12 levels.\n\nExclusion Criteria:\n\n1. Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study. Patients who have had surgery within 4 weeks.\n2. Patients who have received capecitabine or who are on warfarin\n3. Patients who had their final breast surgery more than 12 weeks prior to study start.\n4. Phase Ib: patients who have not received neoadjuvant immunotherapy and\u002For do not plan to continue treatment with immunotherapy for at least the first cycle of study treatment.\n5. Objective evidence of breast cancer.\n6. Metastatic disease\n7. Carcinomatous meningitis or active parenchymal brain metastases.\n8. Estimated creatinine clearance \\\u003C 60 ml\u002Fmin\n9. History of allergic reactions attributed to compounds of similar chemical or biologic composition to TM or capecitabine.\n10. Pregnant women are excluded from this study because TM has the potential to have teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with TM, breastfeeding should be discontinued if the mother is treated with TM.\n11. Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti- retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with TM.","80 Years",{"count":522,"type":22},204,[189,190],"There are two parts to this study. It is a phase 1b followed by a randomized phase 2 study to assess whether adding 3 years of adjuvant tetrathiomolybdate (TM) to standard 6 months treatment of adjuvant capecitabine and pembrolizumab in high risk for relapse triple negative breast cancer.\n\nIn the phase 1b part of the study, TM is added to adjuvant capecitabine and pembrolizumab in high risk for relapse triple negative breast cancer (RCB 2, 3, risk for relapse \\>60% at 5 years) after completion of neoadjuvant chemo-immunotherapy and surgery to establish the safety of the combination. This will be followed by a randomized phase 2 clinical trial of adjuvant TM and capecitabine vs capecitabine alone.\n\nIf pembrolizumab was administered in the neoadjuvant setting, it may be continued in the adjuvant setting per investigator discretion.",[526,527],"Triple Negative Breast Cancer","Residual Disease",[529,527],"Triple Negative Breast cancer","2026-04-15",{"date":532,"type":41},"2026-04-20",{"date":534,"type":41},"2024-11-26",{"date":536,"type":22},"2036-06-26",{"name":47,"class":48},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":545,"targetDuration":547,"studyType":496,"phases":4,"briefSummary":548,"conditions":549,"keywords":552,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":564,"leadSponsor":566,"locationsCount":76},"100589324","psychological-trauma-post-traumatic-stress-disorder-and-resilience-in-adults-with-congenital-heart-disease-100589324","NCT06952933","Psychological Trauma, Post-Traumatic Stress Disorder, and Resilience in Adults With Congenital Heart Disease","PTSD in ACHD","Inclusion Criteria:\n\n* Congenital heart disease diagnosis, age \\>= 18 years\n* Enrolled in CHI registry\n* English proficiency for survey completion\n* Access to an internet connection. Can be via computer or handheld device.\n\nExclusion Criteria:\n\n* Any who opt out\n* Age \\\u003C 18 years\n* No diagnosis of congenital heart disease\n* Not enrolled in CHI registry\u002Funable to access Internet",{"count":546,"type":22},1000,"3 Months","The purpose of this study, entitled \"Psychological trauma, post-traumatic stress disorder, and resilience in adults with congenital heart disease in a large population sample\", is to evaluate for exposures during a lifetime with congenital heart disease that may be associated with higher likelihood of developing PTSD.\n\nPrimary aim:\n\n\\- Identify individual patient characteristics (medical, psychosocial, socioeconomic, etc.) that are associated with a diagnosis of PTSD.\n\nSecondary aims:\n\n* Calculate the prevalence of those meeting PTSD criteria in the ACHD population using the \"gold standard\" diagnostic clinician interview, while using the same data to validate a PTSD screening self-report survey in the ACHD population.\n* Determine the role of resilience in ACHD patients using a validated screening survey to assess its protective role toward PTSD.\n\nHypotheses:\n\n* There are certain exposures (e.g. post-surgical pain, ICU delirium, bullying due to CHD) that are associated with a higher incidence and odds of meeting PTSD criteria.\n* \"Gold standard\" diagnostic interviews will most accurately estimate the prevalence of PTSD in ACHD which has been overestimated on prior screening-based studies, although the scope of the problem is still great.\n* Patients with a higher resilience score will show an association with a lower risk of PTSD.",[550,551,303],"Adult Congenital Heart Disease","Congenital Heart Disease",[553,554,555,556,557,558,559],"adult congenital heart disease","achd","congenital heart disease","pediatric cardiology","ptsd","post-traumatic stress disorder","resilience","2026-03-23",{"date":562,"type":41},"2026-03-25",{"date":72,"type":41},{"date":565,"type":22},"2026-08",{"name":47,"class":48},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":574,"targetDuration":4,"studyType":23,"phases":575,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":586,"locationsCount":97},"100533041","trail-study-feasibility-and-pilot-100533041","NCT06220656","TRAIL Study: Feasibility and Pilot","ThyRoid Active Monitoring and Intervention Longitudinal (TRAIL) Study: Feasibility and Pilot","Inclusion Criteria:\n\n* Participants must be ≥18 years of age.\n* Participants must be able and willing to provide informed consent or have a surrogate capable of providing same.\n* Participants must be absent of symptoms referable to the nodule: dysphagia or nodule physically visible and\u002For bothersome to patient.\n* Participants' thyroid nodule must have a TI-RADS rating of 4 or 5.\n* Participants thyroid nodule must be ≤2 cm in largest diameter.\n* Participants must be being considered for biopsy.\n* Participants with a prior history of papillary thyroid cancer are eligible.\n\nExclusion Criteria:\n\nPatients who fall into one of the following categories will NOT be eligible for this study:\n\n* Adults who are unable to provide informed consent.\n* Patients for whom biopsy is not a consideration.\n* Patients with a prior history of thyroid cancer other than papillary thyroid cancer.\n* Patients with a history of radiation to the neck.\n* Patients who are athyroidal (thyroid gland has been removed or patient has only lingual thyroid tissue).\n* Patients who have ultrasound evidence of one or more of the following:\n* Airway invasion of the nodule.\n* Nodule adjacency to\u002Finvading the recurrent nerve.\n* Extra-thyroidal invasion by the nodule.\n* Patients who have metastasis to cervical lymph nodes (confirmed by needle biopsy if ultrasound suspicious), distant metastases, if identified) testing not required, not usual care)\n* Patients who have already had a biopsy of the nodule being considered for inclusion in the study.\n\nTRAIL Pilot Integrated QRI: Inclusion\u002FExclusion Criteria\n\nInclusion Criteria for Study Patient Participants:\n\n* Participants must meet the eligibility requirements above and will be or have been approached about enrolling in the pilot study.\n* Participants must be willing to allow audio recorder presence and \u002F or willing to be interviewed by the QRI team.\n\nExclusion Criteria for Study Patient Participants:\n\n-Patients who are not willing to allow audio recorder presence and\u002For not willing to be interviewed by QRI team will be excluded from this study.\n\nInclusion Criteria for Study Staff Participants:\n\n* Staff must be willing to audio record their communications with patients about enrolling in the study.\n* Staff must be willing to participate in interviews with QRI team about their views of the study.\n\nExclusion Criteria for Study Staff Participants:\n\n-Staff members who are not willing to participate in audio taping of recruitment discussions and\u002For interviews with QRI team about their views of the study will be excluded.",{"count":21,"type":22},[25],"This is a pilot study to compare two ways of managing newly identified thyroid nodules that are likely to be cancerous based on ultrasound result and which under usual care would undergo immediate biopsy.\n\nThe main goals of this pilot study are 1) compare anxiety at 6 months in each treatment arm using the validated instrument Anxiety-CA, 2) measure thyroid quality of life in each treatment arm\n\nParticipants will be randomized to one of two groups:\n\n1. immediate biopsy (usual care)\n2. Active monitoring (serial ultrasound based monitoring and close clinical follow-up)",[578,579,580],"Thyroid Nodule","Thyroid Neoplasms","Thyroid Cancer","2026-03-19",{"date":560,"type":41},{"date":584,"type":41},"2025-05-01",{"date":45,"type":22},{"name":47,"class":48},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":496,"phases":4,"briefSummary":597,"conditions":598,"keywords":601,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":97},"100577080","study-of-icg-fluorescence-imaging-in-open-fracture-and-infection-patients-100577080","NCT06793644","Study of ICG Fluorescence Imaging in Open Fracture and Infection Patients","Prospective Observational Study of ICG Fluorescence Imaging in Open Fracture and Infection Patients: Early Comparison With a Novel Imaging Device","cBPI","Inclusion Criteria:\n\n* Patients 18 years of age or older.\n* Open extremity fracture, planning for management with external fixation, internal fixation or joint fusion.\n* Fracture Related Infection, planning for management with debridement and possible removal of hardware.\n* Will have all planned fracture care surgeries performed by a participating surgeon or delegate.\n* Provision of informed consent.\n\nExclusion Criteria:\n\n* Inability of patient to provide informed consent\n* Fracture of the hand.\n* Iodine allergy.\n* Burns at the fracture site.",{"count":596,"type":22},10,"The purpose of this study is to determine whether an indocyanine green (ICG) fluorescence imaging system (cBPI) can be used to provide surgeons with information about bone health or bone blood flow. This will help surgeons better understand the healing potential of bone and relative risk of complication. This is important to help surgeons select the most appropriate treatment for severe traumatic injuries and infections.",[599,600],"Fractures, Bone","Trauma Injury",[602,603,604],"Immunofluorescence","Orthopaedic Trauma","Infection","2026-03-17",{"date":581,"type":41},{"date":608,"type":41},"2025-06-10",{"date":610,"type":22},"2027-10",{"name":47,"class":48},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":622,"conditions":623,"keywords":625,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":97},"100597838","phase-1-aby-029-glioma-trial-100597838","NCT07063693","ABY-029 Glioma Trial","Phase 1 Trial of ABY-029 Fluorescence in Patients With High-Grade Glioma","Inclusion Criteria:\n\n1. Clinical diagnosis of presumed high-grade glioma, based on image data.\n2. Tumor judged to be suitable and planned for open cranial resection.\n3. Valid informed consent by participant.\n4. Age ≥ 18 years old.\n5. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Prisoners\n2. Individuals who are pregnant or breast feeding.\n3. Participants on any experimental or approved anti-EGFR targeted therapies\n4. Elevated kidney or liver function tests (levels greater than 2.5 times the normal limit) from laboratory tests conducted as part of standard-of-care screening of prospective surgical participants no earlier than 30 days prior to surgery.\n5. Any condition which, in the opinion of the clinical investigator, contraindicates research participation.",{"count":620,"type":22},33,[189],"The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach brain tumors so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.",[624],"Intracranial Tumor",[328,329,330,331],"2026-03-07",{"date":628,"type":41},"2026-03-10",{"date":630,"type":41},"2026-02-17",{"date":632,"type":22},"2028-12-31",{"name":47,"class":48},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":23,"phases":644,"briefSummary":645,"conditions":646,"keywords":651,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":97},"100607973","electronic-patient-reporting-of-symptoms-and-unmet-needs-to-connect-patients-with-advanced-cancer-to-palliative-care-services-100607973","NCT07195513","Electronic Patient Reporting of Symptoms and Unmet Needs to Connect Patients With Advanced Cancer to Palliative Care Services","\"PRO-CONNECT\" Patient-Reported Outcomes to Coordinate Supportive Care for Unmet Needs During Cancer Treatment","PRO-CONNECT","Inclusion Criteria\n\n1. Age ≥18 years.\n2. Diagnosis of unresectable or metastatic, incurable thoracic, gastrointestinal, or breast solid tumor.\n3. Receiving active cancer-directed therapy longitudinally in the outpatient oncology clinic and expected to continue treatment.\n\nExclusion Criteria\n\n1. Members of vulnerable populations, including infants, minors, individuals unable to provide informed consent, and those who are incarcerated or imprisoned at the time of enrollment.\n2. Already established with palliative care, defined as having a scheduled future palliative care appointment, a pending referral, or a visit with palliative care within the past 90 days.\n3. Unable to provide informed consent in English.\n4. Cognitive impairment that, in the judgment of the treating clinician, would preclude study participation.",{"count":643,"type":22},90,[25],"This study is testing whether electronic surveys can help patients with advanced cancer report their symptoms and care needs so their doctors can connect them to palliative\u002Fsupportive care services sooner. The goal is to see if this approach can make it easier for patients to get support for symptoms, quality of life, and other needs during cancer treatment.",[647,648,649,650],"Palliative Care Referral","Advanced Cancer","Palliative Care, Health Services","Metastatic Cancer (Different Solid Tumour Types)",[652,653,654,655,648,656],"ePROs","Patient Reported Outcomes","Palliative Care","Supportive Care","Metastatic Cancer","2026-03-06",{"date":628,"type":41},{"date":660,"type":41},"2026-02-25",{"date":662,"type":22},"2028-12",{"name":47,"class":48},""]